Zacks.com on MSN1d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
PipelineReview.com2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, NJ, USA I March 20, 2025 I Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) ...
Medical Dialogues2d
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy
Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...
Medindia2d
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
Pharmabiz1d
US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy
US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy: Basel Saturday, March 22, 2025, 09:00 Hrs [IST] Novartis announced that oral Fabhalta (ip ...
pharmaphorum2d
Novartis buys Pharming priority review voucher for a song
Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...
Fierce Pharma2d
Calling UK 'uninvestable,' pharma giants demand revamp of drug cost control policy
Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...
Fierce Healthcare4d
RFK Jr.'s HHS picks up Biden admin legal fight against 340B rebates
The Department of Health and Human Services (HHS) has filed for summary judgment in its favor regarding lawsuits brought by ...
EurekAlert!5d
WIN Consortium leading the future of precision cancer medicine
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
pharmaphorum8d
EMA starts review of Novartis' latecomer PD-1 drug tislelizumab
The EU regulator has started a review of Novartis' PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the drug ...